Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer

Trial Profile

Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Afatinib (Primary) ; Cetuximab (Primary)
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms AFACET
  • Most Recent Events

    • 07 Dec 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 12 Nov 2018 New trial record
    • 08 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top